Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (46)

2024

  1. 18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry

    Journal of Clinical Medicine, Vol. 13, Núm. 20

  2. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine, Vol. 129, pp. 78-86

  3. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  4. SER recommendations on treatment of refractory Behçet's syndrome

    Reumatologia Clinica, Vol. 20, Núm. 4, pp. 204-217

2023

  1. Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 137-144

  2. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

    Frontiers in Immunology, Vol. 14

  3. Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. Characteristics associated with the perception of high-impact disease (PsAID ≥4) in patients with recent-onset psoriatic arthritis. Machine learning-based model

    Seminars in Arthritis and Rheumatism, Vol. 57

  2. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  3. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

    eBioMedicine, Vol. 80

  4. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning

    Arthritis research & therapy, Vol. 24, Núm. 1, pp. 153

  5. Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

    Frontiers in Medicine, Vol. 9

2021

  1. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  2. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  3. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

    BMC Musculoskeletal Disorders, Vol. 22, Núm. 1

  4. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

  3. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 345-352

  4. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis

    Reumatologia Clinica, Vol. 16, Núm. 4, pp. 272-281